Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar
September 3, 2019Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma
Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …
NICE issues new quality standard for cerebal palsy treatment
September 3, 2019Manufacturing and Production, Research and Development
NICE has moved to publish a draft quality standard on the treatment of cerebral palsy (CP) in adults, it has …
Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
September 3, 2019Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …
AstraZeneca shows off Farxiga heart failure efficacy at ESC 2019
September 3, 2019Manufacturing and Production, Research and Development
AstraZeneca has revealed new Phase 3 data illustrating that Farxiga (dapagliflozin), in combination with standard of care, met its primary …
University of Limerick’s Pharmaceutical Manufacturing Technology Centre to expand operations with €5m funding injection
September 3, 2019Manufacturing and Production Ireland, UK, pharma
The Pharmaceutical Manufacturing Technology Centre (PMTC) at the University of Limerick’s Bernal Institute in Ireland has secured €5 million ($5.5 …
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
No-deal Brexit will “make the disintegration of the health service an ever more real prospect”, BMA warns
September 2, 2019Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMA, NHS, UK, brexit, pharma
As the UK hurtles towards a catastrophic and autocratic exit from the European Union, the British Medical Association (BMA) has …
AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
September 2, 2019Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …
Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
September 2, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial
September 2, 2019Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma
Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …
Top Ten most popular articles on Pharmafile.com this week
August 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10
Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.10. NICE …
Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer
August 30, 2019Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis
August 30, 2019Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma
Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …
AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure
August 30, 2019Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …
Using advanced digital capabilities to unlock hard-to-see HCPs access
August 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing digital pharma, pharma, veeva
Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences and ensure they are getting …
Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies
August 29, 2019Research and Development Cancer, Celgene, immatics, immunotherapy, pharma
Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
AstraZeneca lupus drug makes comeback to meet main goal at Phase 3
August 29, 2019Research and Development AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …
Oral contraceptive use as teenager linked to depression as an adult, study says
August 29, 2019Research and Development MDD, depression, hormones, oral contraceptives, psychiatry, psychology
Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a …
Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder
August 28, 2019Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris
Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
Latest content
PSI appoints David Allen as Country Manager for Canada
Qureight appoints Steven Bishop as Chief Medical Officer
Pierre Fabre Laboratories and Iktos announce oncology collaboration
Qureight appoints Rebecca Simmons as Chief Operating Officer
